Compare Wegovy® pricing

Wegovy® Pen

Weekly injection
Semaglutide
GLP-1
Prescription required
Wegovy® Pen clinical trials showed
~21% average weight loss at highest dose, 86% lost more than 5% of body weight.

Wegovy® Pill

Daily pill
Semaglutide
GLP-1
Prescription required
Wegovy® Pill clinical trials showed
~14% average weight loss, 76% lost more than 5% of body weight
1 of 1

See if medication is right for you

knownwell visits covered by insurance
97% of knownwell patients keep weight off after two years
Virtual & in-person visits, with the same clinician

Compare Zepbound® pricing

1 of 1

Zepbound® Kwikpen

Weekly injection
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound® Vial

Weekly injection
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound® Pen

Weekly injection
Tirzepatide
GIP / GLP-1
Prescription required

Zepbound clinical trials showed

~21% average weight loss, 91% lost more than 5% of body weight

Ozempic® pricing

Ozempic®

Weekly injection
Semaglutide
GLP-1
Prescription required
Diabetes medication
Ozempic® clinical trials
~5–6% average weight loss, ~50% lost more than 5% of body weight

See if medication is right for you

Saxenda® pricing

Saxenda®

Daily injection
Liraglutide
GLP-1
Prescription required
Saxenda® clinical trials showed
~8% average weight loss, 62% lost 5% or more of body weight

Foundayo® pricing

Foundayo® Pill

Daily pill
Orforglipron
GLP-1
Prescription required
Foundayo® clinical trials showed
~12% average weight loss, 55% lost more than 10% of body weight

Compare Contrave® & generic pricing

Contrave® 

Daily pill
Naltrexone & bupropion
Prescription required

Naltrexone & Bupropion*

Daily pill
Naltrexone & bupropion
Prescription required
1 of 1

Contrave® clinical trials showed

~6% average weight loss, 48% lost more than 5% of body weight
*Contrave® clinical trials used a proprietary extended-release formulation and may not reflect results with generic naltrexone & bupropion taken separately.

Compare Qsymia® & generic pricing

Qsymia®  

Daily pill
Phentermine & topiramate
Prescription required

Phentermine & Topiramate*

Daily pill
Phentermine & topiramate
Prescription required
1 of 1

Qsymia®  clinical trials showed

~10% average weight loss, 70% lost more than 5% of body weight
*Qsymia® clinical trials used a proprietary formulation and may not reflect results with generic phentermine & topiramate taken separately.

Get bias-free weight management with knownwell

Experts in obesity medicine

Comprehensive, empathetic care from clinicians who specialize in weight management

In-network with insurance

We work with major insurance plans to help make your care and prescription as affordable as possible

Prior authorization support

Our dedicated team helps get your Ozempic® prescription covered — so you're not navigating coverage alone

In-person & virtual availability

Available via telehealth nationwide, with in-person clinics in select cities

Choosing the right option with confidence

When choosing a weight-management medication, clinicians look at several key factors:
Looking at your overall health picture

Conditions like diabetes, cardiovascular disease, high blood pressure, migraines, or mood disorders influence which options are safest, most effective, and least likely to interact with existing health issues or medications.

Thinking about your health goals

Clinicians look at a patient’s target weight-loss percentage. Different treatments produce different average results, so goals such as achieving around 5–10%, 10–15%, or 15%+ total body weight reduction help guide which category of therapy is most appropriate.

Making sure it fits your budget

Prices vary widely among treatment types, and insurance coverage, cash-pay programs, and manufacturer savings offers can dramatically change out-of-pocket costs. Many patients ultimately choose a medication based on realistic long-term affordability.

Considering how your body may react

Each medication category comes with its own pattern of common side effects. Some treatments are more likely to cause gastrointestinal symptoms, while others may lead to things like tingling sensations, dry mouth, changes in mood, sleep disturbances, or blood pressure changes. Matching a patient’s tolerance and sensitivities to the expected side-effect profile is essential.

Finding what works best for your lifestyle

Some people prefer injectable treatments while others want oral daily medications. Others base their choice on whether they want stronger appetite suppression, more craving control, or a specific dosing schedule. Aligning the treatment to a patient’s lifestyle and comfort level helps support long-term success.

Disclaimers

knownwell does not dispense medications and is not a pharmacy. We do not set or control medication prices, and we do not receive any financial benefit based on which medication you choose, or whether you choose to use medication at all. Our role is to provide evidence-based medical guidance and help you access the safest, most effective treatment options for your care.

This page provides a centralized overview of obesity medication cash-pay drug pricing, based on information provided by the relevant drug manufacturer, to help you navigate treatment options, compare therapies, and stay informed throughout your care journey.

All pricing is list pricing based on information provided by the respective drug manufacturers. End user pricing may vary and for more details, consult with the drug manufacturers directly.

Sources

1.
Wilding, J. P. H.,Batterham, R. L.,Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity.New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183. Retrieved fromhttps://www.nejm.org/doi/full/10.1056/NEJMoa2 032183
2.
Wharton, S., Freitas, P.,Hjelmesæth, J., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): arandomised, controlled, phase 3b trial.The LancetDiabetes & Endocrinology, 13(11), 949-963. doi:10.1016/S2213-8587(25)00226-8. Retrieved fromhttps://www.thelancet.com/journals/lan dia/article/PIIS2213-8587(25)0226-8/abstract
3.
Wharton, S.,Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of25 mgin adults with overweight or obesity.New England Journal of Medicine, 393(11), 1077-1087. doi:10.1056/NEJMoa2500969. Retrieved fromhttps://www.nejm.org/doi/full/10.1 056/NEJMoa2500969
See all
4.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. doi:10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1 056/NEJMoa2206038
5.
Sorli, C., Harashima, S., Tsoukas, G. M., et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251-260. doi:10.1016/S2213-8587(17)30013-X. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28110911/
6.
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. doi:10.1056/NEJMoa1411892. Retrieved from https://www.nejm.org/doi/full/10.10 56/NEJMoa1411892
7.
Wharton, S., Aronne, L. J., Stefanski, A., et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796-1806. doi:10.1056/NEJMoa2511774. Retrieved from https://www.nejm.org/doi/full/10.1 056/NEJMoa2511774
8.
Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. doi:10.1016/S0140-6736(10)60888-4. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20673995/
9.
Gadde, K. M., Allison, D. B., Ryan, D. H., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet, 377(9774), 1341-1352. doi:10.1016/S0140-6736(11)60205-5. Retrieved from https://pubmed.ncbi.nlm.nih.gov/21481449/